DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Multiple Myeloma, historical and forecasted epidemiology as well as the Multiple Myeloma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Multiple Myeloma, offering comprehensive insights into the Multiple Myeloma revenue trends, prevalence, and treatment landscape. The report delves into key Multiple Myeloma statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Multiple Myeloma therapies. Additionally, we cover the landscape of Multiple Myeloma clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Multiple Myeloma treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Multiple Myeloma space.
Get a Free sample for the Multiple Myeloma Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/multiple-myeloma-market
Some of the key facts of the Multiple Myeloma Market Report:
The Multiple Myeloma market size was valued at approximately USD 28.7 billion in 2025 and is projected to reach nearly USD 43.6 billion by 2036, registering a compound annual growth rate (CAGR) of 3.3% during the 2026–2036 forecast period.
In May 2026,New clinical data for Tecvayli (teclistamab-cqyv) demonstrate significant survival benefits when the drug is used early in treatment, specifically at a patient’s first relapse with multiple myeloma. The findings show that Tecvayli—a bispecific antibody targeting BCMA and CD3 receptors—delivers superior progression-free survival (PFS) and overall survival (OS) compared to standard multi-drug regimens. Historically reserved for later lines of therapy after patients exhausted multiple options, these data argue strongly for moving Tecvayli up the treatment algorithm. By intervening during the first relapse, clinicians can achieve deeper, more durable remissions, offering a substantial clinical advantage to patients before their disease mutates and becomes highly resistant.
In March 2026, The U.S. Food and Drug Administration has approved the combination of teclistamab (Tecvayli) and daratumumab hyaluronidase-fihj (Darzalex Faspro) for the treatment of adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously undergone at least one line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
In March 2026, Johnson & Johnson (NYSE: JNJ), a global leader in multiple myeloma treatments, announced that the U.S. Food and Drug Administration (FDA) has approved a combination therapy of TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for adults with Relapsed or Refractory Multiple Myeloma (RRMM) who have previously received at least one line of treatment, including a proteasome inhibitor and an immunomodulatory agent. This combination works synergistically to stimulate and activate the immune system, enabling it to target and eliminate myeloma cells expressing the BCMA protein. The approval introduces a promising new treatment option that could potentially serve as a standard of care as early as second-line therapy, addressing the unmet needs of patients, particularly the nearly 40% who experience disease relapse.
In February 2026, AstraZeneca announced that the Phase II (DURGA-3) trial data is projected to be read out in H1 2026, followed by results from the Phase I (DURGA-2) study in H2 2026 and the Phase I/II (DURGA-1) trial in 2027.
In January 2026, Exicure announced that they presented a poster at the 2026 Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), highlighting results from Exicure’s open-label, multicenter Phase II trial (NCT05561751) evaluating burixafor in patients with multiple myeloma undergoing autologous hematopoietic cell transplant (AHCT).
In December 2025, CellCentric announced new data from dose optimization cohorts of its Phase II clinical trial of inobrodib in combination with pomalidomide and dexamethasone in heavily pretreated patients with RRMM. Presented during a poster session at the ASH annual meeting, the data further validate a compelling efficacy and safety profile for the all-oral InoPd regimen, including in patients with high-risk disease and prior exposure to TCEs and BCMA-targeted therapies.
In 2025, the total market size of multiple myeloma in first-line transplant eligible therapies was USD 2,945 million in the US. The highest revenue was captured by DVTd accounting for USD 1,295 million in 2025.
CARVYKTI’s launch remains the strongest CAR-T launch to date. About 60-70% of CARVYKTI utilization was occurring in earlier line settings.
In frontline multiple myeloma clinical studies, DARZALEX was successful and is now considered standard of therapy. DARZALEX has outperformed rivals’ expectations in terms of effectiveness and safety, and expected rule the multiple myeloma market.
Key Multiple Myeloma Companies: Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others
Key Multiple Myeloma Therapies: Regeneron Pharmaceuticals, Sanofi, Arcellx, Gilead (Kite), AbbVie (TeneoOne), Bristol-Myers Squibb, LYNOZYFIC (linvoseltamab), SARCLISA (isatuximab-irfc), Anito-cel (anitocabtagene autoleucel; formerly CART ddBCMA), Etentamig (ABBV-383/TNB-383B), BMS-986393 (CC-95266), Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA
In the 7MM, the US recorded the highest number of Incident cases of multiple myeloma accounting for 34,097 cases in 2025, which are expected to continue increasing through 2036.
Among the EU4 and the UK, Germany accounted for the highest number of multiple myeloma cases, followed by the UK and Germany, whereas Spain accounted for the lowest number of cases in 2025.
In the US, the 65+ age group accounted for ~73% of multiple myeloma cases in 2025, while patients 55–64 years represented ~17%, and
Incident cases of multiple myeloma in the US represent a significant and gradually increasing disease burden, largely driven by an aging population and improved survival outcomes resulting from advances in therapeutic options.
The presence of a large precursor population, including MGUS and smoldering multiple myeloma, highlights a considerable latent pool of individuals at risk of progression. Over time, a proportion of these patients transition to symptomatic disease, which contributes to the sustained growth of the diagnosed multiple myeloma patient population.
Multiple Myeloma Overview
Multiple Myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell responsible for producing antibodies. In MM, abnormal plasma cells multiply uncontrollably in the bone marrow, leading to impaired immune function, bone damage, anemia, kidney problems, and increased risk of infections. The disease is typically chronic and progresses over time, with symptoms including bone pain, fatigue, frequent infections, and high calcium levels. Treatment often involves a combination of chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, and supportive care to manage symptoms and slow disease progression.
To Know in detail about the Multiple Myeloma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Myeloma Market Forecast
Multiple Myeloma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Multiple Myeloma Epidemiology Segmentation:
The Multiple Myeloma market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:
Total Incident Cases of Multiple Myeloma
Total Symptomatic Incident Cases of Multiple Myeloma
Gender-specific Incident Cases of Multiple Myeloma
Age-specific Incident Cases of Multiple Myeloma
Transplant Eligible and Ineligible Cases in Multiple Myeloma
Total Treated Cases Across the Lines of therapies
Download the report to understand which factors are driving Multiple Myeloma epidemiology trends @ Multiple Myeloma Epidemiology Forecast
Multiple Myeloma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Myeloma market or expected to get launched during the study period. The analysis covers Multiple Myeloma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Multiple Myeloma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Multiple Myeloma Therapies and Key Companies
LYNOZYFIC (linvoseltamab): Regeneron Pharmaceuticals
SARCLISA (isatuximab-irfc): Sanofi
Anito-cel (anitocabtagene autoleucel; formerly CART ddBCMA): Arcellx/Gilead (Kite)
Etentamig (ABBV-383/TNB-383B): AbbVie (TeneoOne)
BMS-986393 (CC-95266): Bristol-Myers Squibb
Zevorcabtagene Autoleucel: Carsgen Therapeutics
Descartes 08: Cartesian Therapeutics
GC012F: Gracell Biotechnology Shanghai Co., Ltd.
CID-103: CASI Pharmaceuticals
STI-1492: Sorrento Therapeutics
CARVYKTI (ciltacabtagene autoleucel): Johnson & Johnson Innovative Medicine
TALVEY (talquetamab): Johnson & Johnson Innovative Medicine
ABECMA: Bristol-Myers Squibb and Bluebird bio
SARCLISA: Sanofi
Discover more about therapies set to grab major Multiple Myeloma market share @ Multiple Myeloma Treatment Landscape
Multiple Myeloma Market Drivers
Rising global prevalence of multiple myeloma due to aging populations.
Advances in targeted therapies, immunotherapies, and CAR-T cell treatments improving patient outcomes.
Increasing adoption of novel combination therapies and personalized medicine approaches.
Growing awareness and early diagnosis through improved diagnostic technologies.
Expansion of reimbursement and healthcare infrastructure in emerging markets.
Multiple Myeloma Market Barriers
High cost of innovative therapies limiting patient access, especially in developing regions.
Complex treatment regimens leading to patient non-compliance.
Safety and adverse effect concerns associated with long-term therapy.
Limited availability of specialized treatment centers for advanced therapies like CAR-T.
Regulatory hurdles and lengthy approval timelines for new drugs.
Scope of the Multiple Myeloma Market Report
Study Period: 2022–2036
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Multiple Myeloma Companies: Regeneron Pharmaceuticals, Sanofi, Arcellx, Gilead (Kite), AbbVie (TeneoOne), Bristol-Myers Squibb, Carsgen Therapeutics, Cartesian Therapeutics, Gracell Biotechnology Shanghai Co., Ltd., CASI Pharmaceuticals, Sorrento Therapeutics, Johnson & Johnson Innovative Medicine, Bristol-Myers Squibb and Bluebird bio, Sanofi, and others
Key Multiple Myeloma Therapies: LYNOZYFIC (linvoseltamab), SARCLISA (isatuximab-irfc), Anito-cel (anitocabtagene autoleucel; formerly CART ddBCMA), Etentamig (ABBV-383/TNB-383B), BMS-986393 (CC-95266), Zevorcabtagene Autoleucel, Descartes 08, GC012F, CID-103, STI-1492, CARVYKTI (ciltacabtagene autoleucel) TALVEY (talquetamab), ABECMA, SARCLISA, and others
Multiple Myeloma Therapeutic Assessment: Multiple Myeloma current marketed and Multiple Myeloma emerging therapies
Multiple Myeloma Market Dynamics: Multiple Myeloma market drivers and Multiple Myeloma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Multiple Myeloma Unmet Needs, KOL’s views, Analyst’s views, Multiple Myeloma Market Access and Reimbursement
To know more about Multiple Myeloma companies working in the treatment market, visit @ Multiple Myeloma Clinical Trials and Therapeutic Assessment
Table of Contents
1. Multiple Myeloma Market Report Introduction
2. Executive Summary for Multiple Myeloma
3. SWOT analysis of Multiple Myeloma
4. Multiple Myeloma Patient Share (%) Overview at a Glance
5. Multiple Myeloma Market Overview at a Glance
6. Multiple Myeloma Disease Background and Overview
7. Multiple Myeloma Epidemiology and Patient Population
8. Country-Specific Patient Population of Multiple Myeloma
9. Multiple Myeloma Current Treatment and Medical Practices
10. Multiple Myeloma Unmet Needs
11. Multiple Myeloma Emerging Therapies
12. Multiple Myeloma Market Outlook
13. Country-Wise Multiple Myeloma Market Analysis (2022–2036)
14. Multiple Myeloma Market Access and Reimbursement of Therapies
15. Multiple Myeloma Market Drivers
16. Multiple Myeloma Market Barriers
17. Multiple Myeloma Appendix
18. Multiple Myeloma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
